European journal of pharmacology
Cure8 research brief
Why This Matters
The study identifies a TSPO-targeting compound (koumine) that improved disease and intestinal barrier function in mouse models of ulcerative colitis and links the effect to changes in energy metabolism—an emerging area of interest in IBD pathogenesis and potential therapy.
Who Should Pay Attention
Researchers, clinicians interested in UC pathophysiology, and scientists working on mitochondrial/energy metabolism or TSPO-targeted drug discovery.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This is a preclinical laboratory study using dextran sulfate sodium–induced UC in mice and TSPO-knockout animals. The authors also used metabolomics to profile energy-related metabolites and linked koumine treatment to specific changes (for example, higher DL-glyceric acid and lower acetyl-CoA and 3-phenyllactic acid).
The findings suggest a mechanism (TSPO-mediated regulation of energy metabolism) that could protect the intestinal barrier in UC, but the work is in animals and does not establish safety or effectiveness in people. Additional studies would be needed before any clinical application.
Keep In Mind
Results come from mouse models and metabolomics analyses; translational relevance to humans is unproven and requires further preclinical validation and clinical testing.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationEuropean journal of pharmacology
AuthorsBojun Xiong, Siyu Lai, Shumei Cai +7 more
InstitutionDepartment of Pharmacology, School of Pharmacy, Fujian Medical University, Fuzhou 350122, China; Fujian Key Laboratory of Drug Target Discovery and Structural and Functional Research, School of Pharmacy, Fujian Medical University, Fuzhou 350122, China. Electronic address: xiongbojun@mail.fjmu.edu.cn.
Study typeJournal article
Indexed viaPubMed
Source typeResearch paper
PublishedOct 23, 2026, 12:00 AM
Content availableJournal abstract
Conflict statement: Declaration of Competing Interest ☒ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Liandan Xiaoyan Formula ameliorates DSS-induced ulcerative colitis through altering the metabolism of bile acids by regulating the FXR-FGF15 signaling pathway.
The study links a traditional herbal formula to improved colitis in mice and to changes in bile-acid metabolism through the FXR–FGF15 pathway, suggesting a mechanistic route that could inform future preclinical or...
New coumarin-piperazine derivatives alleviate inflammatory bowel diseases as IL-6 inhibitors by targeting NF-κB pathway
The study describes new small molecules that target IL‑6 and NF‑κB and showed anti-inflammatory effects in laboratory and mouse colitis models, signaling a potential early-stage drug-discovery direction relevant to IBD...
Fraxin alleviates intestinal epithelial cell necrosis in ulcerative colitis by inhibiting the P2Y₁₄R/cAMP/PKA/CREB signaling pathway.
Preclinical evidence that a natural compound (Fraxin) can reduce epithelial necrosis and inflammation in UC models points to a potential new target (P2Y14R/cAMP/PKA/CREB) for future drug research and possibly novel...